The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?

EuroIntervention 2017;12:1684-1687. DOI: 10.4244/EIJV12I14A277

Department of Cardiology, Bern University Hospital, Bern, Switzerland


In the year of its 40th anniversary, percutaneous coronary intervention (PCI) has evolved from balloon angioplasty over bare metal stents to drug-eluting stents (DES) and has, more recently, witnessed the advent of fully bioresorbable scaffolds (BRS). New-generation DES constitute the current benchmark in PCI and are indicated in all patient and lesion subsets1, with excellent early (one-year rate of stent thrombosis <1%, one-year clinical restenosis rate <5%) and late outcomes (rates of very late stent thrombosis beyond one year: 0.1-0.2% per year, rates of clinical restenosis beyond one year: 1-2% per year)2,3. Indeed, PCI has matured into the most ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Discover the new country in the Valve for Life initiative, Portugal.